Amgen has priced Lumakras at $17,900 per month – equivalent to around $215,000 per year – which is a little lower than expected but still in the same ballpark as many other targeted cancer drugs.

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...